Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio Allena Pharmaceuticals, Inc., a business developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, and Althea Technologies, a leading contract manufacturing firm providing development and manufacturing services, today announced a licensing contract under which Allena has obtained the exceptional worldwide privileges to Althea’s broad hyperoxaluria portfolio including product patents, regulatory info and development data related to oxalate degrading enzymes. This license contract strengthens Allena’s ongoing study and development activities for ALLN-177, its delivered enzyme therapy orally, and helps advance the company’s clinical development system for individuals with hyperoxaluria danmark apotek .
However, a research group of the department of Legal Medicine and Psychiatry of the University of Granada, coordinated by professor Antonio Hern’ndez Jerez, has developed a new strategy to obtain this information by screening the pericardial fluid. Related StoriesAmputation isn’t wound healingVISERA 4K UHD endoscopy program provides surgeons 4x resolutionMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideThe need for his research lies in the multiple advantages of this fluid with regard to others. Pericardial liquid is certainly plasma ultrafiltered from the serous vessel surrounding the heart, a watertight compartment separated from blood. Blood analysis usually presents a issue: matrix interferences, such as red cells, proteins, fats, etc., which complicate this technique.